{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001690","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.020172+00:00","generated_at":"2026-05-16T11:02:44.536982+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Vistagen releases corporate presentation highlighting nose-to-brain neuroscience platform","bullets":["Presentation dated January 2026 describes nose-to-brain neurocircuitry for CNS disorders.","No financial data, pipeline updates, or milestones disclosed in the filing excerpt.","VTGN common stock trades on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001690","json":"https://secwatch.observer/filing/0001628280-26-001690.json","markdown":"https://secwatch.observer/filing/0001628280-26-001690.md","text":"https://secwatch.observer/filing/0001628280-26-001690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026001690/0001628280-26-001690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026001690/vtgn-20260109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:02:44.536982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}